Condiciones de salud que Raíz de valeriana puede ayudar a apoyar.
Valerian (Valeriana officinalis) has a long traditional history as a sedative and anxiolytic. Clinical evidence is mixed: some trials show significant anxiolytic effects while others find no advantage over placebo. It appears to work via GABAergic mechanisms, with valerenic acid acting at GABA-A receptors. The German Commission E approves it for nervous unrest and sleep disorders.
A 2022 systematic review in Frontiers in Pharmacology (7 RCTs in children and adolescents with ADHD) found 'fair indication of efficacy and safety' for Valeriana officinalis in treating ADHD symptoms. A notable open-label study by Gromball et al. (2014) in 169 primary-school children showed a combined valerian-lemon balm preparation (640 mg valerian + 320 mg lemon balm daily for 7 weeks) significantly reduced hyperactivity, inattention, impulsivity, and sleep problems. Evidence remains preliminary, limited by small samples and absence of large-scale placebo-controlled trials.
Valerian root (Valeriana officinalis) has been used in European medicine since ancient Greece for nervousness, restlessness, and insomnia. Active valerenic acid and valepotriates modulate GABA-A receptors. Multiple RCTs and a systematic review support sleep quality improvements at 300–600 mg/day; a 2021 phytotherapy review rated it one of three plants with the most clinical evidence for anxiety-related insomnia. German Commission E and ESCOP carry approved monographs.
Valerian root, most studied in children in combination with lemon balm, showed improvement in sleep disturbances in 80.9% of 918 children under age 12 in a large observational study, with excellent tolerability and no medication-related adverse events over 4 weeks. A 2014 observational study in 169 primary school children also showed highly significant parent-rated sleep improvements.
Valerian root (Valeriana officinalis) has centuries of traditional European use as a sleep aid, recognized by the German Commission E for sleep disturbances. Valerenic acid modulates GABA-A receptors and partially agonizes 5-HT5A serotonin receptors highly expressed in the suprachiasmatic nucleus, the circadian pacemaker. A systematic review and meta-analysis (PMC 2020) confirmed sleep quality improvement.
Valerian root (Valeriana officinalis) has European traditional medicine approval and clinical evidence for anxiety and nervous tension. German Commission E and ESCOP approve it for restlessness and nervous tension. Active valerenic acid modulates GABA-A receptors. Clinical reviews consistently include it among botanicals showing anxiolytic effects for mild anxiety and stress.
A 2020 double-blind RCT (n=88) found valerian root (530 mg/day for 4 weeks) significantly reduced severity, disability, and daily-life impact of tension-type headache compared to placebo (p<0.001). The proposed mechanism involves smooth muscle relaxation of pericranial vessels and GABAergic CNS calming. Evidence is currently limited to tension-type headache; no comparable RCT data exist for other headache types.
Valerian root (Valeriana officinalis) contains phytoestrogenic compounds and has been evaluated in a double-blind RCT of 68 menopausal women, showing significant reductions in hot flash severity and frequency versus placebo over 8 weeks. Evidence is preliminary but originates from a controlled clinical trial.
Valerian root (Valeriana officinalis) has been used as a sedative in European traditional medicine for centuries and has been reviewed in numerous clinical trials. Evidence suggests it may improve sleep quality and reduce sleep latency, particularly in chronic insomnia, though study results are mixed. German Commission E has approved it for restlessness and sleep disturbances.
Valerian root (Valeriana officinalis) contains phytoestrogenic and GABAergic constituents and has been studied for menopause-related sleep disturbances and hot flashes. A randomized double-blind clinical trial of 100 postmenopausal women with insomnia found 30% experienced improved sleep quality with valerian vs. 4% on placebo. Evidence for hot flash reduction is also present but mixed.
Valerian root's primary active constituent, valerenic acid, acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission without directly generating GABA. In vitro and in vivo studies further show inhibition of GABA-transaminase (reducing GABA breakdown), modulation of glutamate release via metabotropic glutamate receptors, and animal-study evidence of increased norepinephrine and dopamine following valepotriate treatment. These converging mechanisms establish a scientifically documented influence on multiple neurotransmitter systems.
Valerian root (Valeriana officinalis) has been used for centuries in European traditional medicine for anxiety, stress, and nervous tension. Clinical evidence is mixed but some studies show reductions in anxiety. Compounds from valerian interact with GABA, melatonin, and serotonin receptor systems. Mayo Clinic notes that in some studies people reported less anxiety and stress with valerian use.
Valerian root is a traditional medicinal plant with established use for anxiety and insomnia, conditions highly prevalent during perimenopause. NCCIH acknowledges its study for menopausal symptoms. GoodRx and clinical perimenopause guidance list valerian for sleep cycle disruption and anxiety in perimenopausal women.
Valerian has sedative and GABAergic properties relevant to PMS-related insomnia and anxiety. An RCT evaluating valerian capsules for premenstrual mood and behavioural symptoms found a significant decrease in symptom severity. Valerian also appeared in the PMSoff combination RCT which demonstrated significant PMS benefit.
In a prospective randomized placebo-controlled trial (n=37), 800 mg/day of valerian for 8 weeks significantly improved RLS symptoms and reduced daytime sleepiness in patients with Epworth Sleepiness Scale scores ≥10. A 2023 crossover RCT in hemodialysis patients also showed valerian significantly reduced RLS scores, though less effectively than gabapentin.
Multiple RCTs and systematic reviews document valerian's effects on sleep maintenance outcomes including reduced wake-after-sleep-onset (WASO) and fewer nocturnal awakenings, though evidence is inconsistent across studies. A 2006 meta-analysis of 16 RCTs (n=1,093) showed a statistically significant relative risk of improved sleep of 1.8 (95% CI 1.2–2.9). The 2020 Shinjyo et al. systematic review (60 studies, n=6,894) found improvements in subjective sleep quality and NREM stage 3 time, with GABAergic sedation proposed as the underlying mechanism.
Valerian (Valeriana officinalis) root extract has been used since antiquity for insomnia and nervous tension, and is approved by the German Commission E for sleep disturbances due to nervousness. Multiple RCTs and meta-analyses report improved sleep quality and reduced sleep latency, though evidence quality is variable. The 2020 systematic review and meta-analysis (Shinjyo et al.) found significant benefit across 36 RCTs.
Valerian root (Valeriana officinalis) has been used in European traditional medicine for centuries as a sedative and sleep aid. A 2006 meta-analysis in the American Journal of Medicine of 16 RCTs (n=1,093) found a statistically significant benefit for improved sleep quality (relative risk 1.8; 95% CI 1.2–2.9). Its active constituents valerenic acid and valepotriates modulate GABA-A receptors and inhibit GABA catabolism. Evidence quality is moderate due to methodological heterogeneity across trials.
A well-established European medicinal herb for anxiety and nervous restlessness. Valerenic acid enhances GABAergic activity, reducing anxiety and improving sleep. Commission E and ESCOP monographs approve its use for stress-related nervous restlessness, with clinical trial support.
Valerian root has been traditionally used as a spasmolytic for gastrointestinal complaints including colic, nervous indigestion, and IBS-related cramping. Preclinical pharmacology confirms antispasmodic activity on smooth muscle of the gastrointestinal tract via potassium-channel activation and calcium channel blockade. No adequately powered human RCTs specifically addressing GI abdominal discomfort as a primary endpoint have been published.
Valerian (Valeriana officinalis) has centuries of use in European herbal medicine for nervous conditions, anxiety, insomnia, and mild depression. German Commission E and ESCOP monographs support its use for restlessness and sleep disturbance associated with depression. Clinical evidence is primarily for anxiety and sleep, with depression as a comorbid condition.
Valerian root has one of the longest documented histories as an anticonvulsant herb. In 1592, Fabio Colonna reported that powdered valerian root controlled his own epilepsy; by the late 18th century, it was considered among the best available treatments for seizures in Europe. Preclinical studies support anticonvulsant activity via GABAergic mechanisms, though human clinical trial evidence is lacking.
Valerian root (Valeriana officinalis) has traditional use as an antispasmodic and sedative for uterine cramping and is listed among antispasmodic herbs for dysmenorrhea in Western herbal medicine. Limited clinical research exists; one small RCT suggested benefit for dysmenorrhea pain. Its valerenic acid components act on GABA receptors and have smooth muscle relaxant activity.
Valerian root has documented traditional use for migraine headache based on its CNS-calming and smooth muscle-relaxant properties. One small Iranian clinical study (Mirzaee et al., 2015) investigated valerian in migraine sufferers and reported positive findings, but this study has not been independently replicated and modern migraine management guidelines do not include valerian. The primary evidence base remains traditional.
Valerian root has traditional use in European herbalism as a muscle relaxant and antispasmodic. Commission E and ESCOP recognize valerian for nervous tension and muscle spasm. Its active constituents (valerenic acid, isovaleric acid) act on GABA-A receptors and produce muscle-relaxant effects. Scientific evidence for muscle tension specifically is primarily preclinical, with most human RCTs focused on sleep.
Valerian root has been used in European traditional medicine since antiquity for nervous system complaints including anxiety, insomnia, and nervous tension. Its valerenic acid components modulate GABA-A receptors, providing the scientific basis for its traditional anxiolytic and sedative properties.
Valerian root (Valeriana officinalis) is cited in multiple herbal pertussis protocols as a calming nervine that eases the neurological component of the cough reflex, reduces anxiety, and promotes sleep during the exhausting paroxysmal stage. Dr. Christopher Hobbs places it in the antispasmodic category for pertussis, and herbalist clinical guides recommend it specifically to calm cough-reflex nerves in children with whooping cough.
Valerian root has been used traditionally as a muscle relaxant and nerve analgesic specifically indicated for sciatica in European and Ayurvedic herbal medicine. It contains valerenic acid and valepotriates that modulate GABA receptors and exert antispasmodic effects. Animal research supports its ability to reduce neuropathic pain behaviors; human clinical evidence for sciatica specifically remains limited.
Valerian root (Valeriana officinalis) has a traditional history of use for snoring through its sedative and antispasmodic effects on respiratory tract tissue and sleep quality improvement. Traditional folk medicine prescribes valerian for snoring combined with thyme or fenugreek. Valerian essential oil is included in commercial anti-snoring essential oil formulations alongside lavender and chamomile.
Volver